Assessing the impact of antibiotic therapy on MRSA in hospitalized children
Official title: NAsal MEthicillin-resistant Staphylococcus (NAMES): a Prospective Study to Assess the Impact of Antibiotic Therapy on Nasal Colonization with Methicillin-resistant Staphylococcus Aureus (MRSA) in Hospitalized Children
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06872099 · Data updated 2026-11-12
This study is trying to see how antibiotic treatment affects the presence of MRSA in hospitalized children aged 1 to 16 years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year to 16 Years |
| Sex | All |
| Enrollment | 76 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia, Pavia) |
| Status | Recruiting |
| Started | November 6, 2021 |
| Main results expected | February 19, 2025 |
| Study ends | March 19, 2025 |
| Registry record updated | March 12, 2025 |
| Trial ID | NCT06872099 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are hospitalized children aged between 1 and 16 years who can provide informed consent through their parents or legal guardians.
✕Probably not a fit
Patients who may not benefit from this study include those under 1 year old, those with oncologic or hematologic diseases, and those admitted to the Pediatric Intensive Care Unit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate how antibiotic therapy affects nasal colonization with Methicillin-resistant Staphylococcus Aureus (MRSA) in hospitalized children aged 1 to 16 years. It addresses the growing concern of antimicrobial resistance (AMR) by focusing on the patterns of antibiotic use in pediatric patients, who may respond differently to treatments compared to adults. The study will involve collecting data from children admitted to the hospital, excluding those with specific conditions such as oncologic or hematologic diseases. The goal is to optimize antibiotic usage and reduce unnecessary prescriptions in this vulnerable population.
Why it matters
Potential benefit: If successful, this study could lead to improved antibiotic prescribing practices in children, reducing the incidence of MRSA and enhancing patient outcomes.
How similar studies have gone: Other studies have shown success in optimizing antibiotic use in pediatric populations, making this approach both relevant and necessary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: · All the hospitalized children, aged between 1 and 16 years. * Informed consent signed by parents or legal tutors Exclusion Criteria: · All the hospitalized children admitted to the Unit of Oncologic/Hematologic disease or children affected with an hematologic disease also if admitted to the General Paediatric Ward. * All the hospitalized children admitted to the Paediatric Intensive Care Unit (PICU) * All the hospitalized children aged \< 1 years old * Children with parents or legal tutor who eventually refuse to sign the study consent form
Where it's running
-
Fondazione IRCCS Policlinico San Matteo, SC Malattie Infettive 1
Pavia, Pavia, Italy Recruiting
Study contacts
- Study coordinator: Alessandra Ricciardi, MD
- Email: a.ricciardi@smatteo.pv.it
- Phone: +390382501543
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Trimethoprim-sulfamethoxazole versus clindamycin for children with invasive MRSA infections
This will see if trimethoprim-sulfamethoxazole works as well as clindamycin to treat invasive MRSA infections in children aged 60 days to 18 years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.